Haematologica, Vol 92, Issue 7, 994-995 doi:10.3324/haematol.10802
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mathews, V.
Right arrow Articles by Chandy, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mathews, V.
Right arrow Articles by Chandy, M.

Acute Promyelocytic Leukemia

Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen

Vikram Mathews*,, Maria Thomas*, Vivi M Srivastava°, Biju George*, Alok Srivastava*, Mammen Chandy*

* Department of Haematology, Christian Medical College, Vellore, India
° Cytogenetics Unit, Christian Medical College, Vellore, India

Correspondence: Vikram Mathews, Department of Haematology, Christian Medical College, Vellore, 632004 India. Phone: international +91.416.2282891. Fax: international +91.416.2232035. E-mail: vikram{at}cmcvellore.ac.in

Ninety-eight newly diagnosed cases of PML-RAR{alpha}positive APL were treated with a regimen of single agent ATO. FLT3 activating mutations were seen in 33% and an additional cytogenetic finding was noted in 23.2%. FLT3 activating mutations were significantly associated with a bcr3 PML-RAR{alpha}isoform (p=0.012) and a delay in achieving a molecular remission (p=0.022). Neither FLT3 activating mutations nor secondary cytogenetic changes had an impact on clinical outcome.

Key words: acute promyelocytic leukemia, arsenic trioxide, FLT3 mutation, cytogenetics.




This article has been cited by other articles:


Home page
 BloodHome page
M. S. Tallman and J. K. Altman
How I treat acute promyelocytic leukemia
Blood, December 10, 2009; 114(25): 5126 - 5135.
[Abstract] [Full Text] [PDF]